Natco Pharma Ltd share price logo

Natco Pharma Ltd (NATCOPHARM)

₹1260.351.65%

bell
Get free price alerts. Set up your Free investment account to get Live Prices.
Overview
News
Financials
Q1 2024 Results
Technicals

Analyst Rating

based on 12 analysts

BUY

75.00%

Buy

8.33%

Hold

16.67%

Sell

Based on 12 analysts offering long term price targets for Natco Pharma Ltd. An average target of ₹1063.75

Source: S&P Global Market Intelligence

Natco Pharma Ltd Share analysis

Source: S&P Global Market Intelligence

Performance

  • Day's Low

    Day's High

    ₹1,255
    ₹1,311
  • 52 Week's Low

    52 Week's High

    ₹708.05
    ₹1,311
1 Month Return+ 6.24 %
3 Month Return+ 28.65 %
1 Year Return+ 79.58 %
Previous Close₹1,281.45
Open₹1,286.00
Volume21.60L
Upper Circuit-
Lower Circuit-
Market Cap₹22,952.03Cr

Key Statistics

P/E Ratio16.58
PEG Ratio0.5
Market Cap₹22,952.03 Cr
P/B Ratio2.19
EPS35.2

Mutual Fund Holdings

Funds HoldingsPrev. 6M
Tata Equity P/E Fund Direct Plan GrowthTata Equity P/E Fund Direct Plan Growth1.67%
Tata Small Cap Fund Direct GrowthTata Small Cap Fund Direct Growth1.33%
SBI Magnum Midcap Fund Direct GrowthSBI Magnum Midcap Fund Direct Growth0.43%
Canara Robeco Emerging Equities Direct Plan Growth OptionCanara Robeco Emerging Equities Direct Plan Growth Option0.24%
Mahindra Manulife Small Cap Fund Direct GrowthMahindra Manulife Small Cap Fund Direct Growth0.84%

Company Information

Natco Pharma Limited is an international, RD focused pharmaceutical company that specialises in the development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs). Natco sells products in over 40 countries, and provides contract manufacturing services for other pharmaceutical companies. The company was originally founded in 1981, and has since enjoyed significant growth, launching a variety of products and earning a number of milestones such as a compulsory license from Bayer for its patent protected anticancer drug Nexavar in 2012, and various first-to-market generic drugs including HEPCINAT (generic Sofosbuvir) and Epclusa (a single tablet regimen for the treatment of genotypes 2 and 3 chronic hepatitis C virus HCV infection). In 2021, Natco had 8 launches in the domestic market and acquired Dash Pharmaceuticals LLC in the US. Natco has 8 international subsidiaries, including the Philippines, Australia, Brazil and the US, constantly achieving the first generic to market for a variety of drugs. Natco's ambition for growth looks set to continue in 2022, with a number of new launches planned.

Share Price: ₹1260.35 per share as on 18 Jul, 2024 04:01 PM
Market Capitalisation: ₹22,952.03Cr as of today
Revenue: ₹1,068.30Cr as on March 2024 (Q1 24)
Net Profit: ₹386.30Cr as on March 2024 (Q1 24)
Listing date: 27 Dec, 1995
Chairperson Name: G S Murthy
OrganisationNatco Pharma Ltd
HeadquartersHyderabad
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Natco Pharma Ltd

  • Natco Pharma Mulls Acquisitions to Strengthen Base Business - 28 Jun, 2024

    Natco Pharma is considering acquisitions in Rest of the World markets to strengthen its base business. The company recorded its highest ever consolidated revenue and profits during FY24, with a growth of 47% and 94%, respectively. It recently invested $2 million in Cellogen Therapeutics Private Ltd and is optimistic about first-time generics in agro business.

  • Natco Pharma's Low P/E Ratio Reflects Diminished Earnings Outlook - 14 Jun, 2024

    Natco Pharma Limited's low P/E ratio of 15.2x reflects a diminished earnings outlook, with estimated earnings decreasing by 22% each year for the next three years. While recent times have been advantageous for Natco Pharma as its earnings have been rising faster than most other companies, shareholders may not see strong share price growth in the near future under these circumstances.

  • Natco Pharma Gains for Fifth Straight Session - 11 Jun, 2024

    Natco Pharma Ltd's stock continues to rise, gaining 5.12% on the NSE and around 18.42% in the last month. The company is a constituent of the Nifty Pharma index, which has also seen gains in the past month.

  • Natco Pharma Aims for Over 20% Growth in Next 3-4 Years - 10 Jun, 2024

    Debt-free Natco Pharma aims to achieve over 20% growth in both top and bottom lines for the next 3-4 years, with a cash reserve of Rs 2,000 crore and no major capex planned. The company is targeting niche markets with limited competition.

  • Natco Pharma Stock Rises After ICICI Add Call - 07 Jun, 2024

    Natco Pharma Ltd's stock rises by 4.93% to Rs 1084.7 after ICICI Securities' add call with a target price of Rs 1145. The company reported a consolidated total income of Rs 1110.30 crore for Q1 FY25, up 39.56% from the previous quarter.

  • Natco Pharma Reports Strong Revenue and Profit Growth - 05 Jun, 2024

    Natco Pharma's revenue from operations increased by 56% YoY to Rs. 661 crore in FY23-24, while net profit grew by 85% YoY to Rs. 173.6 crore. QoQ, revenue grew by 8.3% to Rs. 182 crore in Q4 FY23-24, and net profit rose by 19% to Rs. 50 crore.

  • Natco Pharma Beats Market Forecasts with Revenues of ₹41b - 30 May, 2024

    Natco Pharma exceeded expectations and beat market forecasts with revenues of ₹41b, arriving 5.3% ahead of estimates. Analysts predict a 16% improvement in revenue to ₹47.8b by 2025, with EPS predicted to leap 24% to ₹95.74. The consensus price target held steady at ₹1,022.

Insights on Natco Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 24.45% to 24.97% in Jun 2024 quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 212.7 Cr → 386.3 Cr (in ₹), with an average increase of 44.9% per quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 16.14% to 17.45% in Jun 2024 quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 795.6 Cr → 1.11K Cr (in ₹), with an average increase of 28.3% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, NATCOPHARM stock has moved up by 8.0%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 49.71% of holdings in Jun 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 129.1% return, outperforming this stock by 111.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Zydus Lifesciences Ltd has given 96.8% return, outperforming this stock by 17.2%

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 4.08% to 2.67% in Jun 2024 quarter

Company Financials

Value in ₹ crore
Q'1 24Q/Q Change
Revenue
₹1,068.30Cr
↑40.83%
Net Income
₹386.30Cr
↑81.62%
Net Profit Margin
36.16%
↑28.96%
2023Y/Y Change
Revenue
₹2,707.10Cr
↑39.20%
Net Income
₹715.30Cr
↑320.76%
Net Profit Margin
26.42%
↑202.29%
Value in ₹ crore
2023Y/Y Change
Total Assets
₹5,566.80Cr
↑9.03%
Total Liabilities
₹864.80Cr
↓5.35%
Value in ₹ crore
2023Y/Y Change
Operating Cash Flow
₹784.40Cr
↑1,259.45%

Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
49.71%
0.00
Foreign Institutions
17.45%
8.15
Mutual Funds
2.67%
-34.60
Retail Investors
24.97%
2.12
Others
5.2%
-7.47

Key Indicators

Natco Pharma Ltd Valuation

Natco Pharma Ltd in the last 5 years

  • Overview

  • Trends

Lowest (11.55x)

January 17, 2024

Today (16.58x)

July 16, 2024

Industry (56.76x)

July 16, 2024

Highest (90.32x)

April 6, 2022

LowHigh

Earnings and Dividends

  • Natco Pharma Ltd Earnings Results

    Natco Pharma Ltd’s net profit jumped 40.07% since last year same period to ₹386.30Cr in the Q4 2023-2024. On a quarterly growth basis, Natco Pharma Ltd has generated 81.62% jump in its net profits since last 3-months.

    Read More about Earnings Results
  • Natco Pharma Ltd Dividends February,2024

    In the quarter ending December 2023, Natco Pharma Ltd has declared dividend of ₹1.25 - translating a dividend yield of 0.74%.

    Read More about Dividends

Technicals Summary

Bearish

Neutral

Bullish

Bullish

Natco Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.

Frequently Asked Questions

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Natco Pharma Ltd shares.

Natco Pharma Ltd (NATCOPHARM) share price today is ₹1260.35

Natco Pharma Ltd is listed on NSE

Natco Pharma Ltd is listed on BSE

  • Today’s highest price of Natco Pharma Ltd is ₹1311.
  • Today’s lowest price of Natco Pharma Ltd is ₹1255.

PE Ratio of Natco Pharma Ltd is 16.58

PE ratio = Natco Pharma Ltd Market price per share / Natco Pharma Ltd Earnings per share

Today’s traded volume of Natco Pharma Ltd(NATCOPHARM) is 21.60L.

Today’s market capitalisation of Natco Pharma Ltd(NATCOPHARM) is ₹22952.03Cr.

Natco Pharma Ltd(NATCOPHARMPrice
52 Week High
₹1311
52 Week Low
₹708.05

Natco Pharma Ltd(NATCOPHARM) share price is ₹1260.35. It is down -3.86% from its 52 Week High price of ₹1311

Natco Pharma Ltd(NATCOPHARM) share price is ₹1260.35. It is up 78.00% from its 52 Week Low price of ₹708.05

Natco Pharma Ltd(NATCOPHARMReturns
1 Day Returns
-21.1%
1 Month Returns
6.24%
3 Month Returns
28.65%
1 Year Returns
79.58%